Myungmoon Phar (017180) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Myungmoon Phar KRW 958, price KRW 1,222, upside -21.6%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Myungmoon Phar for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,057 KRW – 6,100 KRW · fair‑value band 711.71 KRW – 1,342 KRW · the 1,222 KRW price screens above the 957.71 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 4 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Myungmoon Phar in your weekly email
Every Wednesday you see whether Myungmoon Phar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally.
Show more
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
Stock analysis
Myungmoon Phar (017180) currently trades at 1,222 KRW, while our model-based Fair Value estimate is 957.71 KRW, implying the stock looks roughly 27.6% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 1,948 KRW per share, and 6 of the 14 models we run sit above the 1,222 KRW price.
Bear case: the Earnings-Based group reads lowest at 283.57 KRW, and 8 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 711.71 KRW (bear) to 1,342 KRW (bull), the price of 1,222 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Myungmoon Phar reported revenue of 195B KRW in FY2025 versus 145B KRW in FY2021, a compound +7.8%/yr. Reported net income was 1.9B KRW in FY2025.
Key figures
Market cap 40.8B KRW (≈ $30.0M) · P/S ratio 0.21 · Net margin 1.0% · Return on equity 2.5% · Return on assets (EBIT) 0.8% · Operating margin 0.6% · Revenue (TTM) 197B KRW · Revenue growth (YoY) +4.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −22%, 017180 screens richer than that median.
Fair Value models
Bear 711.71 KRWFair Value 957.71 KRWBull 1,342 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +4.6% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−37.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−37.5%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−23% → 4%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−22% · Below median
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)2% · Below median
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth5% · Above median
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Myungmoon Phar Fair Value". https://www.fairvalue-calculator.com/stock/017180
Frequently asked questions
Is Myungmoon Phar (017180) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 957.71 KRW versus a price of 1,222 KRW, about −22% upside (overvalued).
What is the fair value of 017180?
Our model-based fair value for Myungmoon Phar is 957.71 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,222 KRW.
What is the quality score of 017180?
Myungmoon Phar has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myungmoon Phar (017180)?
Our model-based price target is the fair value of 957.71 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 711.71 KRW, optimistic scenario 1,342 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Myungmoon Phar stock forecast for 2026?
Our models put fair value at 957.71 KRW, about −22% upside versus a price of 1,222 KRW (overvalued). Cautious scenario 711.71 KRW, optimistic scenario 1,342 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Myungmoon Phar (017180)?
Myungmoon Phar reported trailing-twelve-month revenue of about 197B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Myungmoon Phar (017180)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myungmoon Phar it is 957.71 KRW per share (as of Sep 24, 2026), against a price of 1,222 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Myungmoon Phar stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 017180 trades above its calculated fair value: price 1,222 KRW, fair value 957.71 KRW, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 017180?
No. The price is what the market pays today (1,222 KRW); the fair value is what the company's own numbers justify (957.71 KRW). For Myungmoon Phar the two are 264.29 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Myungmoon Phar worth?
The market values Myungmoon Phar at about 40.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,222 KRW; our models calculate a fair value of 957.71 KRW per share.
What do the bullish and bearish scenarios say about 017180?
Our models span a range for Myungmoon Phar: cautious scenario 711.71 KRW, base 957.71 KRW, optimistic 1,342 KRW per share (as of Sep 24, 2026, price 1,222 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Myungmoon Phar (017180)?
Balance-sheet figures for Myungmoon Phar (as of Sep 24, 2026): return on equity 2.5%, debt of 0.43 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 017180 from its 52-week high?
Myungmoon Phar trades at 1,222 KRW, about 37% below its 52-week high of 1,945 KRW and 16% above the low of 1,057 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 957.71 KRW is for.
Which stocks are comparable to Myungmoon Phar?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myungmoon Phar stock attractive at the current price?
The data as of Sep 24, 2026: price 1,222 KRW, calculated fair value 957.71 KRW (−22%), Quality Score 45/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 017180 calculated?
We run Myungmoon Phar through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 957.71 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Myungmoon Phar itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myungmoon Phar (017180)?
The closing price on Sep 23, 2026 was 1,222 KRW. Our model-based fair value is 957.71 KRW, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myungmoon Phar right now?
Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (711.71 KRW to 1,342 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Myungmoon Phar
How large is the market capitalisation of Myungmoon Phar (017180)?
The market capitalisation of Myungmoon Phar is 40.8B KRW (≈ $30.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Myungmoon Phar (017180)?
The price-to-sales ratio of Myungmoon Phar is 0.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Myungmoon Phar (017180)?
The net margin of Myungmoon Phar is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myungmoon Phar (017180)?
The return on equity (ROE) of Myungmoon Phar is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myungmoon Phar (017180)?
On an EBIT basis the return on assets of Myungmoon Phar is 0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myungmoon Phar (017180)?
The operating margin of Myungmoon Phar is 0.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myungmoon Phar (017180)?
Revenue at Myungmoon Phar is growing +4.6% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Myungmoon Phar (017180)?
Earnings per share at Myungmoon Phar are growing +83.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Myungmoon Phar (017180) generate?
The free cash flow of Myungmoon Phar is −8.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myungmoon Phar (017180) carry?
The net debt of Myungmoon Phar is 92.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Myungmoon Phar in the live analysis
One click puts Myungmoon Phar on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
